Developing technology that will allow patients to regrow tissues in their own body, possibly revolutionizing the transplant market.
Morphoceuticals, Inc.’s mission is to establish a basis for limb regeneration and discovery of novel regenerative interventions.
Morphoceuticals originated from the work of co-founders
The team is building a next-generation AI platform to map top-down control of pattern regulation. Levin’s lab has been able to cause limb regeneration in a variety of animals. Morphoceuticals is initiating research to translate this progress from lower animals to mammals.
The frontier of regenerative medicine is a promising market that, estimated at $23 billion in 2018, is expected to increase to $150 billion by 2026.